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ABSTRACT

Introduction
This study aimed to examine e-cigarette user reasons for
use, changes in their nicotine concentrations, and factors associated
with changes in their chosen nicotine concentrations.
Methods
Data was from a convenience sample of 788 adult ecigarette users recruited in Mississippi, examining user
demographics, current/history of use, and their perceptions. 396
(34.64%) participants submitted a survey. Forty participants were
excluded. The final sample was 356 for analyses.
Results
Participants had a mean e-cigarette time of use of about 24
months, a mean current nicotine concentration level of 7.767
mg/ml, and a mean initial nicotine concentration level of 8.851
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mg/ml. About 56% were using their e-cigarettes for a harm
reduction reason. Participants had a mean decrease of 1.084 mg/ml
of their self-selected nicotine concentration (t=-1.747, p=0.082).
Both linear regression models significantly explained the variance
in the self-selected nicotine change score.
Conclusions
Participants reported a decrease in selected nicotine
concentration. Total time of e-cigarette use was a significant
predictor within the two linear regression models on the selfselected nicotine concentration change score, where increases in
time of use were associated with greater decreases in the nicotine
concentration change score. Vapers utilizing the e-cigarettes for
harm reductions reasons had a greater decrease in the nicotine
concentration change score than vapers using their e-cigarette for
non-harm reduction reasons. Our findings reflect the existing
literature and suggests that vapers will decrease their nicotine. Our
study highlights the importance for additional research around
changes in self-selected nicotine concentrations, and the use of ecigarettes for harm reduction or smoking cessation purposes.
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CHAPTER 1
INTRODUCTION

Of the more than 4,000 chemicals in tobacco, nicotine is thought to be the major reasons
for tobacco dependence. The United States (U.S.) Centers for Disease Control and Prevention
(CDC) reports that tobacco use is associated with over 480,000 deaths each year across the U.S.,
making it the largest cause of preventable mortality.1–3 While smoking prevalence has steadily
decreased in the U.S. since 2005 from 20.9% of adults to 15.1% of adults, about 36.5 million
adults, in 2015, there is still room for improvement. 2 The decline in smoking prevalence is
expected to continue as 68% of smokers indicated they wanted to quit smoking entirely in a 2015
CDC survey.2
The U.S. Food and Drug Administration (FDA) has approved two categories of smoking
cessation pharmacotherapies: nicotine replacement therapy (NRT), and non-nicotine
medications.4 NRT medications cover drugs intended to manage nicotine withdrawal side effects
by providing controlled doses of nicotine. NRT can be found in different forms, including
nicotine patches, nicotine lozenges, or nicotine gum. While non-nicotine cessation medications
act on neurotransmitters in an effort to safeguard patients from the same side effects. 4 Nonnicotine medications include Chantix and Zyban.4
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Chantix has been shown to have the greatest positive impact on cessation, among FDA
approved cessation methods. Garrison et al. found that Chantix had success rates ranging from
21.9% to 34.6% in various studies.5 Zyban, nicotine lozenges, and nicotine patches have been
shown to have success rates of 16.8%-23.1%, 19.9%, and 17.7% respectively. 6,7 However,
smoking cessation clinical trials usually report greater rates of cessation due to the controlled
environments they can provide or encourage, with actual success rates around 10% lower than
reported.8 In addition to methods approved by the FDA, there are other approaches smokers use
to aid in their quit attempts.
Electronic cigarettes (e-cigarettes) use has increased at an alarming rate since their
introduction in the U.S. in 2007. Originally developed by pharmacist Hon Lik, e-cigarettes
commonly use a battery powered heating element to vaporize and deliver an aerosolized nicotine
solution to be inhaled by the user.9–13 E-cigarettes offer a unique nicotine delivery mechanism
which has encouraged the public to develop a widespread belief that e-cigarettes have potential
to aid in smoking cessation.10,11,14–20 Rahman et al. explored this belief, reporting about an 18%
cessation rate at the six-month follow up.15 This success rate is similar to that of NRTs, and
Zyban, which are currently approved by the FDA for use in tobacco cessation. 6,7 In addition,
Nutt et al. conducted a relative harm analysis concluding e-cigarettes were 96% less harmful
than conventional cigarettes (CC) when evaluating the potential harm to their users and
bystanders.21 E-cigarette users have also reported the belief that e-cigarettes may inhibit nicotine
cessation, while previous literature has reported they can cause side effects, and expose
individuals to various chemicals at levels higher than recommended by the U.S. Environmental
Protection Agency.8,9,11,16,22,23
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Previous research has explored the characteristics of use among electronic cigarette users,
and the reasons behind these characteristics: showing over 80% of electronic cigarette users are
using their devices with smoking cessation as their main reason for use. 17 Electronic cigarette
users themselves have proposed that electronic cigarettes can help users quit by allowing them to
reduce their e-cigarette nicotine concentration over time.16,18,23 Soule et al. reported e-cigarette
users agreed that tapering down their nicotine concentration helped them quit tobacco. 23 Current
literature has not shown any connections between e-cigarette users’ reasons for using e-cigarettes
and their chosen nicotine concentrations. More research is needed to inform the public and
policy makers on the trends around the use of e-cigarettes and how their use can affect public
health.
This study utilized the Health Belief Model as the theoretical framework; concepts
including, perceived susceptibility, perceived severity, perceived benefits, perceived barriers,
cues to action, and self-efficacy were used to represent portions of an individual’s intent to
complete or initiate an action or behavior.24–29 These concepts are complex in nature, initially
being influenced by various factors of a person’s demographic background that affect how each
individual values each of the constructs.24,26 Due to the complex nature of smoking cessation and
e-cigarette use, subjective norms was used to account for the impact of each individuals’ social
influences.30
This study aimed to answer the following questions to provide evidence to policymakers,
and researchers regarding e-cigarettes and smoking cessation. What are the reasons for use
among electronic cigarette users? Do electronic cigarette users change their nicotine
concentrations to help with smoking cessation? Which factors serve as predictors of change in

3

current electronic cigarette users’ chosen nicotine concentrations in their electronic cigarette
liquid?
The aims of this study were modified, upon completion of the first round of data
collection, to answer the following questions to provide evidence to policymakers, and
researchers regarding e-cigarettes and smoking cessation. What are the reasons for use among
electronic cigarette users? Do electronic cigarette users change their nicotine concentrations?
Which factors are associated with change in electronic cigarette users’ chosen nicotine
concentrations in their electronic cigarette liquid?
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CHAPTER 2
LITERATURE REVIEW

Food and Drug Administration’s Recent Announcement on Tobacco Regulations
In July of 2017, the United States (U.S.) Food and Drug Administration (FDA) released
an announcement detailing a shift of their regulations on tobacco and related products. 31 The
FDA detailed its main goals as protecting children from smoking and reducing morbidity and
mortality associated with tobacco utilization.31 A major component of this announcement
described aims to begin a discussion on reducing nicotine levels in cigarettes to non-addictive
levels.31 The FDA also intends to limit the introduction of new tobacco and electronic nicotine
delivery system (ENDS) products by establishing end dates for new products in August 2021 for
combustible tobacco products and August 2022 for ENDS products. 31 A 2015 study by
Grebenstein et al. demonstrated using lab rats, that lowering the level of nicotine in cigarettes
would lead to a brief increase in the amount of cigarettes utilized but would result in lower usage
levels subsequently.32 Benowitz and Henningfield discussed current studies around lowering
nicotine concentrations in cigarettes with the general consensus that lowering nicotine levels
could reduce nicotine exposure while not increasing cigarette consumption or could reduce
nicotine dependence.33 Sofuoglu and LeSage reviewed current literature on reducing cigarette
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nicotine levels to at or below the reinforcement threshold, showing that the plan could work, but
should be carried out over a longer period of time. 34 They concluded that additional research was
needed to better inform policy recommendations.34
The FDA’s plan could potentially reshape the current tobacco epidemic through a series
of changes, by encouraging current smokers to quit, and preventing future generations from
picking up smoking. By preventing the introduction of new products and lowering the nicotine
levels to non-addictive levels, the U.S. could see large movements of smokers switching to
alternative products to either continue or taper off their addictions. Under these new time
restrictions for the introduction of tobacco and ENDS products, continued research needs to be
carried out to monitor all related changes and trends. ENDS research has continually increased
since their introduction however, understanding the individual and societal impacts of these
products is paramount from a public health standpoint. This study intends to collect data on
ENDS use to better inform policy creation.
Tobacco and Nicotine Addiction
The U.S. Centers for Disease Control and Prevention (CDC) reports that tobacco use is
associated with over 480,000 deaths each year across the U.S., making it the largest cause of
preventable mortality.1–3 Smoking prevalence has steadily been on the decline in the U.S. since
2005, from 20.9% of adults to 15.1% of adults in 2015, about 36.5 million adults. 2 The decline in
smoking prevalence is expected to continue as 68% of smokers indicated they wanted to quit
smoking entirely, in a 2015 CDC survey.2
Of the more than 4000 chemicals in tobacco, nicotine is thought to be the major reason
for tobacco dependence.6,35 When nicotine is absorbed in the human body, it acts on hormones
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and neurotransmitters including dopamine, serotonin, norepinephrine, acetylcholine, vasopressin,
and beta-endorphins.6,36 Nicotine affects the central nervous system by increasing alertness,
improving memory, improving concentration, and decreasing anxiety. 6,36 These effects provide a
temporary calming and euphoric high, producing a strong addiction to nicotine in a short
timeframe.6,36
Due to the nature of the addiction, tobacco dependence is considered a chronic relapsing
disease.6,36 Achieving smoking cessation is as difficult as quitting alcohol, cocaine, or heroin,
with multiple relapses expected throughout the process. 6,35 Smokers looking to quit have
pharmacologic, and/or behavioral options to help them achieve success and combat some
withdrawal symptoms they may experience, including increased irritability or anxiety, new or
worsening depression, weight gain, increased appetite, cravings to keep using tobacco, trouble
sleeping, or difficulty thinking.4,35 If successful in their cessation attempt, former tobacco users
will also benefit from lower risks for cardiovascular disease, respiratory disease, and various
types of cancer.35
Food and Drug Administration Approved Smoking Cessation Methods and Their Effectiveness
The FDA has multiple approved pharmacologic agents to aid in smoking cessation; in
addition, there are other interventions that smokers may find helpful in their quit attempts, such
as counseling, cognitive behavioral therapy or other behavioral interventions. 4 There are two
categories of pharmacologic cessation aids, nicotine replacement therapies (NRT) and nonnicotine medications.4,35 Over-the-counter NRTs include nicotine patches (also available with a
prescription), nicotine gum, and nicotine lozenges. Nicotine inhalers, and nicotine sprays are
available with a prescription.4,35 Non-nicotine pharmacologic cessation agents include Chantix
(varenicline tartrate), and Zyban (bupropion hydrochloride), both of which are available with a
7

prescription.4,35 Behavioral therapies have also been shown to improve success rates associated
with quitting tobacco products.6,35,36
Chantix has been shown to have the greatest positive impact on cessation, among FDA
approved cessation methods. Garrison et al. found that Chantix had success rates ranging from
21.9% to 34.6% in various studies.5 Zyban, nicotine lozenges, and nicotine patches have been
shown to have success rates of 16.8%-23.1%, 19.9%, and 17.7% respectively. 6,7 Smoking
cessation clinical trials usually report greater rates of cessation due to the controlled
environments they can provide or encourage, with actual success rates being around 10% lower
than reported.8 In addition to cessation methods approved by the FDA, there are other
approaches smokers use to aid in their quit attempts. Recent trends have shown a widespread
belief that electronic cigarettes (e-cigarettes) have potential to aid in smoking cessation. 10,11,14–20
Simmons et al. conducted focus groups with current and former smokers on their beliefs
surrounding e-cigarettes with their participants reporting they greatly benefited from their use, as
a cessation aid, in addition to seeing improvements in their health. 18 A recent study conducted by
Ayers et al. reported that the most prevalent reason for ENDS use, found in their Twitter content
analysis, was quitting combustible tobacco products (43%, 95% CI (39-48)). 19
Electronic Cigarette History and Regulations
E-cigarettes, or ENDS, are battery-operated devices designed to be used to inhale an
aerosol solution typically containing nicotine. The history of electronic cigarettes can be traced
back to 1962, when Herbert Gilbert initially developed a tobacco-less smoking device that would
produce a non-nicotine vapor to be inhaled by the user.37 Gilbert’s precursor to modern ecigarettes never achieved commercial success and failed to enter the market. 37 Modern ecigarettes were developed by Chinese pharmacist Hon Lik and received the first patent on his
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device in China during 2003.9–13,38 International and U.S. patents came later in 2007.9,39 As a
previous pack a day smoker, Hon Lik developed ENDS to help himself and others achieve
tobacco cessation after his father passed away from smoking-related lung cancer. 13
In the U.S., the most recent regulations regarding e-cigarettes and related products came
from the FDA in 2016.40 The FDA moved e-cigarette products under their tobacco regulations. 40
This move set the minimum age to purchase e-cigarettes to 18 across the U.S. and allows the
FDA to regulate the, “manufacture, import, packaging, labeling, advertising, promotion, sale,
and distribution,”40 of e-cigarette products.40 Some states, like Hawaii in 2016, have opted to
increase the minimum age of purchase and/or ban e-cigarette usage in public places. 41 Outside
the U.S., countries have taken varying approaches to e-cigarettes. Some countries such as
Australia, Brazil, Canada, Mexico, Panama, Singapore, and Switzerland have opted to outright
ban e-cigarettes.9 However, the United Kingdom’s (U.K.) Medicines and Healthcare Regulatory
Agency announced a plan to regulate e-cigarettes as smoking cessation medication in 2014. 12
The U.K. offers e-cigarettes in the same fashion they do as NRT products, in that they are
covered under their national healthcare system as a smoking cessation medication. 12
Electronic Cigarette Terminology, Components, and Fluid
E-cigarette users, or ‘vapers’ as they prefer to be called, can purchase a variety of ENDS,
including cig-alike, e-cigarettes, electronic pipes, electronic cigars, disposable vapes, hookah
pens, and vape mods (highly customizable e-cigarettes). 18,40,42 Whichever version of ENDS a
vaper may use, they do share a few common qualities. Each ENDS utilizes a battery or multiple
batteries to power a heating element, referred to as an atomizer, which vaporizes the fluid
contained in the tank/reservoir to produce a cloud of vapor for the user to inhale. 9,39,40,42 Each
part of the more customizable e-cigarettes can be interchanged to create different setups. The
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original cig-alike e-cigarettes utilized an airflow sensor to initiate vaporization while newer
models use a button clicked and held by its user. 9 The fluid vaporized by the ENDS usually
contains some mixture of propylene glycol , glycerin, nicotine, natural/artificial flavorings, and
occasionally water.9,38,40,42–44
Bahtnagar et al. reported as of 2014 that there were 466 brands, and 7,764 unique flavors
of e-juice in e-cigarettes.9 These numbers are expected to increase as the ENDS industry and
consumer base continues to grow. Some e-cigarettes allow the user to adjust the voltage/wattage
(VW) the device will produce. Higher VW increases the temperature the coil in the atomizer will
reach, which can increase the volume of e-cigarette juice vaporized, adjust the flavor profile.
Decreasing the VW can increase battery life or adjust the flavor. The nicotine concentrations in
e-cigarette fluid ranges from 0 mg/ml to ~50 mg/ml.18,23 Hajek et al. reported that the most
popular nicotine concentrations utilized by vapers was around 18 mg/ml. 11 In a more recent
study, Soule et al. reported 8 mg/ml being the most popular e-cigarette nicotine concentration
used by vapers.23
Electronic Cigarette Safety and Potential for Dependence
Current literature reports e-cigarettes are at least 95% less harmful than convention
cigarettes (CC) and the public would benefit from smokers switching from CC to ecigarettes.9,14,21,45,46 For example, Nutt et al. conducted a relative harm analysis concluding ecigarettes were 96% less harmful than CC when evaluating the potential harm to their users and
bystanders.21 While less harmful than CC, e-cigarettes are not safe and can produce hazardous
substance that users inhale.9,11,21,45 Chen et al. reported e-cigarettes exposed users to average
levels of acrolein and propylene glycol were higher than recommended by the U.S.
Environmental Protection Agency’s guidelines.45 In addition, emissions maximum exposure
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levels of diethylene glycol, and cadmium were at levels higher than the Environmental
Protection Agency’s guidelines.45 Hajek et al. evaluated a study completed in Japan, suggesting
that e-cigarettes are exposing users to formaldehyde at levels 5 to 15 times that of CC. 14 A later
study published in the New England Journal of Medicine followed up on the previous claim
finding negligible formaldehyde levels at lower e-cigarette power settings, lower VW. 14
Formaldehyde was detected at higher power levels or in e-cigarettes with low fluid, however
vapers are able to instantly detect this phenomenon due to a harsh and acrid taste, prompting
them to refill their e-cigarettes or turn down the power. 14
Bhatnagar et al. reported vapers may also be exposed to different particulates, including
tin, iron, nickel, chromium, ceramics, plastics, rubber, or foams when using e-cigarettes. 9 The
metals could come from the type of metal the coil in the atomizer is made. Some e-cigarettes can
control their power output in terms of VW, while some can also control the exact temperature to
which they heat specific metals. To provide an example of this, the Reuleaux RX200 can control
temperatures of the coil if it is made from titanium, stainless steel, or nickel in addition to
controlling the VW it produces.47
In a 2014 study, Polosa et al. reported common adverse events related to e-cigarette use
at 4, 8, 12, and 24-week follow-ups. Adverse reactions included, throat/mouth irritation (35.6%),
dry throat/mouth (28.9%), headache (26.7%), and dry cough (22.2%) at the 4-week follow-up. 8
The prevalence of these adverse events generally declined over time, with 10.5%, 18.4%, 21.2%,
and 5.3% reporting the same events at the 24-week follow-up, respectively. 8 Other adverse
events included dizziness, nausea, sore throat, palpitations, and a choking sensation at lower
prevalence rates.8,48
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The early versions of disposable e-cigarettes released in Poland, the U.K., and the U.S.
had varying efficiencies at vaporizing the nicotine they contained. 38 Goniewicz and colleagues
studied 16 types of e-cigarettes in their ability to vaporize the nicotine they contained, showing
the e-cigarettes studied vaporized between 21% to 85% of the nicotine they contained after 300
puffs.38 Goniewicz et al. also showed that the labeled nicotine concentrations in some brands
may be significantly different from their actual nicotine concentrations. 38 With the advancement
of the e-cigarette industry, improved standards have been set up as well as the improvement of
the various e-cigarette types. The ability and efficiency of an e-cigarette to vaporize its nicotine
may affect vaper dependence.43 The same applies to CC and NRT in their delivery methods and
levels of nicotine exposure.43 Etter and Eissenberg conducted a study to evaluate dependence
levels of e-cigarette, nicotine gum (NRT), and CC users. They found that CC are by far the most
addictive delivery method with e-cigarettes being about addictive or potentially less addictive
than nicotine gum.43 Goldenson et al. reported on high school student use of e-cigarettes, finding
that higher levels of e-cigarette nicotine concentrations increased the odds for participants to still
be vaping at the 6 month follow up.49
Electronic Cigarette Populations Statistics and Economics
The U.S. has seen rapid economic growth in the e-cigarette market, with sales having
almost doubled each year since 2008.9,10,50 In 2014, the CDC reported that about 3.7% of
American adults currently used e-cigarette, with 12.6% of adults having ever tried them. 2 The
CDC reported on the prevalence of electronic cigarette use for 2014 showing men (4.1%) have a
higher rate of use than women (3.4%).51 Adults age 18-24 (5.1%), and age 25-44 (4.7%) have
higher rates than adults age 45-64 (3.4%) and 65+ (1.4%). 51 Non-Hispanic whites (4.6%), and
American Indians/Alaskan Natives (10.7%, 95% CI [5.3, 20.4]) use e-cigarettes at a significantly
12

greater rate than non-Hispanic black (1.8%), non-Hispanic Asian (1.5%), and Hispanic (2.1%)
subgroups.51 Current smokers (15.9%), recent former smokers (22.0%), and long term former
smokers (2.3%) have higher rates of current use of e-cigarettes when compared to those who
never smoked cigarettes (0.4%).51
Xu et al. reported that the sales of electronic cigarettes reached $12 million in 2011, $22
million in 2012, and $28 million in the second quarter of 2013 in the U.S. 10 Correspondingly, the
CDC reported e-cigarettes sales increased about 320% for disposable e-cigarettes, 72% for
starter kits, and 82% for cartridges between 2012 and 2013. 50 Wells Fargo has predicted global
sales for e-cigarettes could grow to $10 billion by 2017.9 With the increasing market and
consumers of e-cigarettes, e-cigarettes have become a focus point for scientific inquiry. Xu
reported on the growth of e-cigarette related articles in PubMed from less than 100 in 2012, to
more than 200 in 2013, and 800 in 2014.10,52 We conducted our own search of PubMed with the
search terms ‘electronic cigarette’, ‘e-cigarette’, ‘e-cig’, ‘electronic vaping device’, ‘personal
vaping device’, ‘electronic nicotine’, ‘electronic nicotine delivery system’, ‘electronic hookah’,
‘electronic cigar’, ‘cig-alike’ or ‘vaper,’ in the titles of articles. Our PubMed search occurred at
the beginning of October 2017 and found 1,041 search results.
Electronic Cigarettes Reasons for Use and Surrounding Opinions
Various reasons for use of e-cigarettes have been provided by vapers, smokers, exsmokers, and non-smokers. Tobacco cessation is a well discussed reason for e-cigarette use, with
many respondents reporting they decrease their e-cigarette fluid nicotine concentration over
time.10,16–19,23,44,53,54 However, more research is still needed to examine the safety and
effectiveness of e-cigarettes as a cessation aid and their overall public health impact before
policy and health recommendations can be made.
13

Tobacco reduction usually involves dual-use of e-cigarettes and some form of tobacco,
like cigarettes or cigarillos, but is a hazard to the user’s health due to the continued use of
tobacco.16,17,23,44 While this method is a matter of concern, Carpenter et al. and Hammond et al.
have reported NRT has been used with the same strategy. 55,56 Tobacco reduction usually uses
nicotine products to reduce or eliminate side effects of tobacco/nicotine withdrawal, if the user
has to go an extended period without their tobacco product, like at work, or on commercial
airline flights. Tobacco replacement or tobacco relapse prevention employs e-cigarettes as a
substitute for tobacco products and is another common reason for use reported by vapers. 16
Tobacco replacement or relapse prevention is another reason for use common with NRT. 16,55
Some vapers use e-cigarettes to circumvent public smoking laws as most smoking bans
don’t include e-cigarettes, another strategy associated with NRT products as well. 19,23,44,55 This is
not the case on commercial airlines, as the U.S. Transportation Security Administration and
individual airline companies, like Delta Airlines, do not allow e-cigarette use onboard
commercial flights and e-cigarettes must be carried in carry-on baggage. 57,58 Recreational use has
also been cited as a reason to use e-cigarettes, this is a cause for concern that will require
additional research on how to curb this phenomenon.23,44,45,53
Respondents from various studies have shared their opinions related to the perceived
benefits associated with e-cigarettes. Perceived benefits for e-cigarettes include a sense of
belongingness in the vaping community, allowing vapers to keep their social surroundings even
if their peers use tobacco, recreating reinforcing habits associated with smoking (personal cues,
hand to mouth, social, drinking, etc.), reducing their withdrawal symptoms with nicotine like
NRT, decreasing/tapering their nicotine concentrations to quit at their own pace, and the variety
of available flavors which enable them to stay away from tobacco and menthol flavors. 16–19,23,46
14

Studies have also reported that some respondents believe e-cigarettes are less harmful and
healthier than CC in addition to other forms of tobacco products. 10,16–18,20,23,44,59,60 Etter reported
participants who were using e-cigarettes to quit smoking, believed they were “better for (their)
health than tobacco.”44 Opposing to the reported perceived benefits, vapers have also reported
perceived risks associated with e-cigarettes, in that they could hinder a smoker from attaining
cessation by potentially maintaining nicotine addiction, the persistence of a craving for tobacco,
exposing e-cigarette users to carcinogens, and other unknown long-term adverse health
effects.16,23
Electronic Cigarettes and Smoking Cessation
E-cigarettes have been promoted as a smoking cessation aid in marketing and advertising
campaigns by their manufacturers, and distributors.10,12,16,61 Grana et al. reported 64% of ecigarette advertisements contained claims related to smoking cessation. 61 In comparison,
Wackowski et al. reported 84% of vapers use e-cigarettes as a cessation method. 17 Rahman et al.
developed a meta-analysis of six studies detailing the effect of e-cigarettes on smoking cessation
and reported an 18% cessation rate by the six-month follow up. 15 This success rate is similar to
that of NRTs, and Zyban. 6,7 Polosa et al. conducted a pilot study in 2011 and a clinical trial in
2014 examining CC use reduction associated with e-cigarette use. 8,48 The pilot study reported
approximately 81% of participants sustained a 50% or greater reduction in CC use while using ecigarettes at 24-weeks follow-up with one-third having achieved complete cessation. 48 Their
clinical trial reported 86% of participants sustained a 50% or greater reduction in CC use at 24weeks follow-up and about 47% achieved complete cessation.8 Polosa et al. concluded as a
tobacco harm reduction strategy, e-cigarettes are a realistic and promising method. 8 However,
both studies started with small samples (n=40, n=50, respectively) and lost participants by the
15

24-week follow up.8,48 The pilot study lost 13 participants while the clinical trial lost 12
participants.8,48
A systematic review examined four e-cigarette clinical trials, and concluded that nicotinecontaining e-cigarettes are not an efficacious method for smoking cessation. 12 The review states
that non-nicotine placebo e-cigarettes may be useful as a substitute of the sensory and behavioral
aspects of smoking.12 One recent systematic review and meta-analysis conducted by El Dib et al.
of e-cigarette randomized control trials concluded that there is very limited evidence on the
impact or efficacy of e-cigarettes in smoking cessation. 62 The authors reported these trials did not
adhere to a standard definition of smoking cessation with each study employing a different
definition and stressed that future e-cigarette trials need to be well-designed and biochemically
validated outcomes need to be measured.62 Future studies in e-cigarette research should employ a
standard definition of smoking cessation and trials need to take into account the opinions and
experiences of current vapers and vapers who successfully terminated their tobacco addiction.
Electronic Cigarette Gradual Reduction and Personalized Nicotine Concentration Strategies
Research on reasons to use e-cigarettes have reported users believe that e-cigarettes can
help combat a smoker’s addiction to nicotine or tobacco through a gradual reduction in their ecigarette fluid nicotine concentration. This strategy has been proposed as a means to end
cigarette smoking at a policy level, by implementing legal limits on the nicotine contained in
CC.31,32,34,63,64 Benowitz et al. conducted a study on tapering nicotine concentrations in CC and
found the participants experienced reduced adverse effects with 25% of their participants (n=20)
achieving cessation even though they didn’t enter the study to quit. 64,65 Benowitz et al. employed
nicotine tapering from cigarettes containing 12mg of nicotine down to 1mg of nicotine over a 10
week period showing that nicotine reduction strategies using e-cigarettes could be beneficial to
16

their users.64,65 Beginning a smoker’s cessation attempt on a standardized level of nicotine may
not produce ideal outcomes for every individual. Every smoker varies in their use of CC or other
tobacco products which might necessitate a more customized cessation plan. Rose et al. has
proposed a personalized smoking cessation strategy tailored to each individual. 66 This strategy
could be useful as cigarettes have been known to have different levels of nicotine, and not every
cessation method works for every person, as shown by the success rates between 16% and 35%
of NRT, Zyban, and Chantix.5–7,67
Soule et al. surveyed vapers on their reasons for using e-cigarettes, finding that vapers
primarily use e-cigarettes for smoking cessation but there are many other reasons for their use. 23
In this study, the perceived benefit of e-cigarettes to taper or reduce nicotine concentrations over
time was rated an average of 5.49 on a scale from 1 to 7. 23 Other qualitative studies have also
reported that vapers decrease their nicotine concentration in their e-liquids over time. For
example, Simmons et al. conducted a series of focus groups on vapers perceptions and intentions
for future use.18 A theme obtained from the groups was that users were intentionally trying to
reduce the amount of nicotine in the e-cigarettes they used, and reported success in doing so
obtaining some of the lowest nicotine concentrations for the brands they used. 18 Camenga et al.
conducted 18 focus groups with an emergent theme of ‘Methods for Smoking Cessation’
containing a prevalent belief that ‘e-cigarette users could gradually reduce or “wean” nicotine
dosage,’ and that smokers may benefit from this elongated process. 16 However, little information
is available regarding the extent of vapers’ chosen nicotine concentration changes over time and
what characteristics of individual users affect the choices made regarding vapers’ chosen
nicotine concentrations over time.
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Theoretical Framework
The Health Belief Model (HBM) has become one of the most widely used behavioral
frameworks, since its introduction in the early 1950s.24–26,29 This model has been employed
extensively in studying personal health behavior and behavioral changes as it provides an
explanation of how an individual’s beliefs affect their choice to engage in or change a health
behavior.24,26 There are six central concepts within the HBM including perceived susceptibility,
perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy. 24–29
These concepts each represent portions of an individual’s intent to complete or initiate an action
or behavior. Perceived susceptibility and perceived severity are interlinked in perceived threat
with susceptibility referring to an individual’s perceived risk to a negative effect and severity
describing the belief of how serious the negative effect is. 24,26,29 Vapers can identify their risk for
a side effect from vaping and how serious they believe that side effect is. Perceived benefits are
the positive outcomes of the action or behavior, while perceived barriers are the costs and
negative predispositions associated with the action or behavior. 24,26,29 Vapers could see less side
effects and more control over their addiction using e-cigarettes when compared to CC or they
could have a negative view on e-cigarettes. Cues to action involve different methods to get a
person ready to carry out the action or behavior with self-efficacy being the person’s belief in
their ability to carry out the action or behavior.24,26,29 A vaper’s support system, might be
inclined to provide a cue to action if they support the use of an e-cigarette for CC cessation. A
vaper’s internal motivation to change a behavior can affect their actions taken to change that
behavior, vapers with more motivation to quit smoking CC, may be more inclined to change
their nicotine concentrations faster.
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These central concepts of the HBM are influenced by a combination or the individuals’
socioeconomic and demographic characteristics, in that a person’s background will affect how
they value and perceive each of the constructs.24,26 The HBM does not have an emphasis on
social norms and the influence of an individual’s peers. 29 Due to the complex nature of smoking
cessation and e-cigarette use, social influences in the form of subjective norms will also need to
be considered. Subjective norms cover the normative beliefs of people around the individual in
question in addition to the individuals value of the referred person, the closer a peer is to the
individual, the more importance or weight the individual might place on the peer’s opinion. 29,30
Intentions of smokers, ex-smokers, and vapers can be described with the HBM, with each
of the six concepts represented in tobacco or e-cigarette use. Mohammadi et al. and Reisi et al.
have conducted studies utilizing the HBM to predict the actions of smokers under the age of 18,
showing that perceived susceptibility, perceived benefits, perceived barriers, and self-efficacy
are all related to tobacco use.27,28 Reisi et al. reported that smokers and non-smokers have
significant differences in perceived susceptibility (p=0.03), perceived benefits (p=0.01), selfefficacy (p<0.001), and cues to action (p=0.007).27 Mohammadi et al. conducted a study of the
HBM related to smoking and reported self-efficacy, and cues to action as significant predictors
of smoking behavior.28 This study will utilize the HBM with the addition of subjective norms as
a theoretical framework to identify predictors of change in vapers’ chosen nicotine
concentrations in their e-cigarette liquid. A diagram of out theoretical framework can be found in
Appendix B.
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Implications for Research
E-cigarette use has increased at alarming rates since their introduction in the U.S. 2
Researchers and their respondents have expressed concern regarding the use of e-cigarettes as a
potential gateway to CC or other tobacco products. As with Hon Lik’s original intention for ecigarettes, research has shown that a majority (84%) of vapers use e-cigarettes for smoking
cessation purposes.17 However, more research on the reasons for e-cigarette use and the extent of
e-cigarette use is needed to better understand their short-term and long-term impact on public
health. Since the FDA’s July 2017 announcement on plans to discuss nicotine levels in CC,
smokers may be more motivated to begin to lower their nicotine levels at a more controlled rate
and could be drawn to NRT, or to e-cigarettes. This potential ‘migration’ of smokers to NRT and
e-cigarettes accentuates the importance for more research on the patterns of use with these
products and research to help inform the development of personalized smoking cessation
strategies tailored to each individual.
Original Objectives
In this study, we aim to:


Determine the reasons for electronic cigarette use amongst current electronic cigarette
users.



Describe changes in current electronic cigarette users’ chosen nicotine concentrations in
their electronic cigarette liquid over a six-month period.



Identify predictors of change in current electronic cigarette users’ chosen nicotine
concentrations in their electronic cigarette liquid.
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Modified Objectives
In this study, we aimed to:


Determine the reasons for electronic cigarette use amongst current electronic cigarette
users.



Describe changes in current electronic cigarette users’ chosen nicotine concentrations in
their electronic cigarette liquid.



Identify factors associated with change in current electronic cigarette users’ chosen
nicotine concentrations in their electronic cigarette liquid.
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CHAPTER 3
METHODS

Hypotheses
Based on a review of the literature in smoking cessation and electronic cigarette use, we
hypothesized that (1) the majority of vapers are using electronic cigarettes with smoking
cessation as their main goal;17 (2) vapers will decrease their chosen concentration of
nicotine ;16,18,23 (3) self-efficacy and cues to action will be the strongest factors associated with
each vapers’ change in their chosen nicotine concentrations over a six-month period. 28,67
Study Design
This study employed a cross-sectional survey, recruiting a convenient sample of
electronic cigarette users. Participants are referred to as ‘vapers’ in this study, current literature
shows they prefer to be identified with this term.18 Electronic surveys were utilized to collect
data on the following elements: reasons for e-cigarette use, future e-cigarette use intentions,
patterns of use, and constructs specified in the theoretical framework within electronic cigarette
users at two time points during the study. The surveys also contained questions aimed at
examining vapers’ chosen nicotine concentrations, smoking cessation strategies, duration of use,
frequency of use, history of cigarette use, history of other tobacco use, and future intentions of
using electronic cigarettes. In addition, vapers’ socio-demographic information was collected.
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To track each vaper, their email address was acquired to distribute the survey. However,
vaper date of birth, address, name, or other personally identifiable information was not collected
to protect the respondents’ identities. All collected personally identifiable information was
maintained in a password protected laptop, or in a secure and undisclosed locked location. Only
research team members have access to personally identifiable information. Confidentiality was
further protected separating personally identifiable information from vapers’ responses into a
separate document. At the end of the study, all personally identifiable information will be deleted
along with the email file to further protect the identity of vapers. Deidentified data will be
maintained on secure files thereafter. This study has been approved by the University of
Mississippi’s Institutional Review Board.
Sample Population and Recruitment Strategy
This study utilized a convenience sampling strategy, producing a non-randomized
sample. All results are reported as observed correlations as we cannot infer causality due to the
sampling design. Recruitment was carried out in person by a research team member in central,
and northern Mississippi vape shops. We gathered the majority of vapers in Oxford, MS to
reduce any travel costs associated with the study. After participants were made aware of their
rights as research participants, they were asked to give written consent, in the form of their email
address, in order to participate in the study. Vapers’ emails were used to link their responses on
the survey with their consent forms. An example consent form can be found in Appendix C.
Necessary sample size was calculated using G*Power, finding that 165 participants will
be needed to meet the analytical needs of this study at the second survey. 68 However, the
literature shows that around 80% of users are using electronic cigarettes with cessation as a
reason and about 60% of the initial sample remained in studies till completion. With these
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adjustments, we proposed to recruit a minimum of 350 participants to maintain enough
participants for statistical analyses at the time of the second survey.
The inclusion criteria for this study are individuals who are 18 years of age or older, and
currently use an e-cigarette at the time of recruitment. Before being asked to participate in the
survey, each person was provided with information on their rights as a research participant and
asked to complete a consent form. Participants were excluded if they are under 18 years of age,
report that they have never used an electronic cigarette before, did not currently use an electronic
cigarette, or did not complete the survey through the demographic section. The emphasis on age
is due to current Mississippi and federal legislation on e-cigarette use, setting the minimum age
to purchase e-cigarette products to 18. Objective 3 utilized an additional exclusion criterion in
that participants had to complete the questions related to this study’s theoretical model. The
inclusion and exclusion criteria were examined using the first three (3) questions of the initial
survey. To show appreciation for their participation and to increase response rate, respondents
were notified that they would receive a $5 Amazon e-gift card sent via email after completing the
survey.
Data Collection
Data collection was carried out via Qualtrics. The initial survey was emailed to the
participant within 48 hours after the completion of their consent form. The survey was
distributed from a University of Mississippi email address to each participant’s provided email
address. To boost the response rate, participants received two email reminders at one week and
two weeks after the distribution email, if we did not have a response from their email address. In
addition, the gift card reward for survey participation was expected to help increase the survey’s
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response rate. All data was stored on Qualtrics until it was transferred to a researcher’s secure
laptop.
Survey Development
The survey was developed in Qualtrics, under a license held by the University of
Mississippi. The first question contained information on who to contact if the participant had any
questions or trouble on/with the survey. The initial survey utilized its second, third, and fourth
questions to filter out any participants who do not meet the inclusion criteria. This was carried
out in a specific order to protect the identities of those participants who do not qualify to
participate. The second question asked the age of the participant to verify they were of a legal
age to use electronic cigarettes. The third question asked if the participant currently used
electronic cigarettes as the survey was intended to assess current users of electronic cigarettes.
The last inclusion/exclusion question requested the participants email address to link their
responses to their consent forms.
Demographic questions were developed based on the CDC’s National Youth Tobacco
Survey and National Adult Tobacco Survey.69,70 Electronic cigarette and conventional cigarette
history of use questions were developed based on questions in the National Youth Tobacco
Survey and National Adult Tobacco Survey, specifically questions attempting to identify the
duration of lifetime use and recent use the specified products. 69,70 The CDC defines a smoker as
someone who has smoked at least one CC in the last month and at least 100 CCs over their
lifetime.70 A question from the National Health Interview Survey was utilized to ask about
tobacco cigarette use.71 The National Adult Tobacco Survey was used to determine if
respondents meet the CDC definition of a smoker. 70 Questions regarding predictors of vaper’s
chosen nicotine concentrations in their e-cigarettes liquid were developed bases on the
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theoretical framework of this study, a study by Kelley Rhoads, a study by Coe et al., and a study
by Soule et al.23,72,73
This survey contained 53 questions, of these nine were required questions: three were for
the inclusion criteria, three asked about nicotine concentrations, two were on time frames
associated with nicotine concentrations, and one asked about their reason for using e-cigarettes.
This survey utilized skip logic to reduce the amount of questions a participant would have to
complete when the questions were not applicable to the participant. If a participant had never
smoked CC, then the survey would skip to the first question after the CC questions. There were
some questions contained within the survey intended to inform future research questions or act as
back up analyses in the event of a high sample attrition rate. These questions pertained to
financial costs associated with e-cigarettes, volume of e-cigarette liquid use, vaper flavor
preferences, and vapers beliefs on flavors impact on their tobacco quit attempts. The
questionnaire was pilot tested with a small sample to check for face validity before deploying it
to our main participants. An example survey can be found in Appendix C.
Study Variable Operationalization
The theoretical framework and current literature in smoking cessation and e-cigarettes
informed the operationalization of variables contained in the survey. Sociodemographic variables
of age (≥18 years), sex, race, ethnicity, and educational attainment were measured the survey.
The survey examined reasons for use using two primary questions and some additional
follow up to confirm the participant uses their electronic cigarette as described. Participants were
asked if they are using e-cigarettes for the following reasons: to circumvent smoking bans, to
reduce how much they smoke CC, to switch their CC for their e-cigarette, to replace their CC for
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their e-cigarette and reduce their nicotine, to quit another form of tobacco, to control their
appetite/for weight loss, for fun, for a buzz/high, or other, with the option to insert their own
answer on a follow up question.
Participants were asked their currently used nicotine concentrations in milligrams per
milliliter (mg/ml), since this is the standard unit used in e-cigarettes. In addition, they were also
be asked the nicotine concentration they used when they first started using their e-cigarette.
Nicotine concentration will be referred to as nicotine level in the survey to allow the participants
to see terminology they are familiar with.
A brief history of use in e-cigarettes and CC was determined through a series of questions
designed to determine the duration and severity of use, in addition to two questions to determine
if the smoker meets the CDC definition of a smoker. The history section asked participants about
usage of e-cigarettes and CC among their family and friends. Peer use of either nicotine delivery
system, served as a basis for the subjective norms in the theoretical construct. Participants’
beliefs were looked at using a series of statements where the participant is asked to identify if
they strongly agree to strongly disagree. Theses belief statements are listed in Appendix A and
were utilized to represent the constructs from the theoretical model. Some of these statements
were positively coded while others were negatively coded to examine the consistency of a
respondent’s answers.
Data Analysis
Descriptive statistics were conducted on the vapers’ sociodemographic characteristics, ecigarette characteristics of use, and CC characteristics of use, including frequencies and
percentages. The e-cigarette characteristics included their reasons for use, future intentions for e-
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cigarette use, their initial nicotine concentration, and their current nicotine concentration. Using
the matched nicotine concentrations of each participant, a paired samples t-test was utilized to
examine the differences between vapers’ initial nicotine concentrations and their current nicotine
concentrations. Two linear regression models were created to identify factors associated with
changes in vapers’ chosen nicotine concentrations. The first model contained the vapers’ ecigarette characteristics of use and their sociodemographic characteristics. The second model
expanded from the first to include the factors from our theoretical model.
An Alpha of 0.05 was used to determine statistical significance. All t values are reported
as two-tailed tests. Statistical analyses were conducted in IBM’s SPSS 25.0, under a license held
by The University of Mississippi.74 Data collected in Qualtrics was downloaded in to an Excel
file and then transferred in to SPSS.

28

CHAPTER 4
RESULTS

Total Sample and Exclusions
Upon completion of the survey collection, consent was received from a total of 788
individuals, of which 396 (34.64%) submitted a survey via Qualtrics. Thirty-three participants
were excluded for not completing the survey through the demographics section. Two participants
responded to the survey twice, their second responses were removed. Four participants were
excluded due to their reported current nicotine concentration level not reflecting a mg/ml format.
One participant was excluded due to an error in reported total time of e-cigarette use in months.
The final sample was 356 for analyses. In addition, 14 participants were excluded from the linear
regression models for not completing the questions related to this study’s theoretical model.
Sample Characteristics
The sample was primarily male, white/Caucasian, non-Hispanic/Latino/a, and had started
or completed their education past a high school degree. The average age of the study sample was
23.8 years. Participants had a mean e-cigarette time of use of about 24 months, a mean current
nicotine concentration level of 7.767 mg/ml, and a mean initial nicotine concentration level of
8.851 mg/ml. The majority of participants planned to keep their nicotine concentrations the same
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in the next 6 months, planned not to quit using their e-cigarette in the next 6 months, primarily
used tank mod e-cigarettes, and used e-cigarettes to replace their CC use. Participants had a
mean time of cigarette use of about 8 years and had a mean of about 3.2 quit attempts. Quitting
‘cold turkey’ or by their willpower alone was the predominant method of cessation utilized by
participants with 185 (58.9%) having reported they attempted this method. Three-hundred and
sixteen participants reported having ever used a cigarette, with 256 reporting they have used at
least 100 cigarettes. Ninety-two participants met the CDC definition of a smoker with at least
100 cigarettes used in their lifetime and at least one used in last month. Table 1 presents the
descriptives statistics of participants’ sociodemographic information. Table 2 presents the
descriptives statistics of participants’ e-cigarette characteristics of use. Table 3 presents the
descriptives statistics of participants’ CC characteristics of use.
Difference in Self-Selected Nicotine Concentration from Initial to Current E-Cigarette Use
Participants reported a mean initial nicotine concentration of 8.851 mg/ml and a mean
current nicotine concentration of 7.767. Participants had a mean decrease of 1.084 mg/ml of their
self-selected nicotine concentration in their e-cigarette nicotine solution from their initial use of
e-cigarettes to their current use of e-cigarettes; however, this decrease was not statistically
significant (t=-1.747, p=0.082). See Table 4 for the results of the paired samples t-test regarding
the change in self-selected nicotine concentration from initial to current use of e-cigarettes.
Factors Associated with Change in Self-Selected Nicotine Concentration from Initial to Current
E-Cigarette Use
Main reason for e-cigarette use were collapsed from nine different options to three
including, harm reduction (reduce cigarette consumption, replace cigarettes, replace cigarette and
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reduce nicotine, and replace other form of tobacco), non-harm reduction (to circumvent smoking
bans, for weight loss/control appetite, for fun, and for buzz/high), and other. Main type of ecigarette used were collapsed from five option to two options including, customizable ecigarettes (tank-mod e-cigarettes and drip mod e-cigarettes) and non-customizable e-cigarettes
(cig-alikes, vape pens, and e-hookahs). Table 5 reports results of linear regression model
examining e-cigarette use characteristics, CC use characteristics, and sociodemographic
characteristics. The model explained 19.6% of the variance in the self-selected nicotine
concentration change score. Collinearity statistics were within an appropriate range. E-cigarette
time of use (months) was a significant predictor, with each one month increase in the time of ecigarette use there was a decrease in nicotine concentration change score of 0.099 mg/ml. There
was a significant difference between individuals using e-cigarettes for a non-harm reduction
reason and individuals using e-cigarettes for a harm reduction reason. Vapers using e-cigarettes
for non-harm reduction reasons had an increase of 3.273 mg/ml on the change score when
compared vapers using e-cigarettes harm reduction reasons.
Table 6 reports results of the second linear regression model, which explained 23.2% of
the variance in the self-selected nicotine concentration change score. Collinearity statistics were
within an appropriate range. Model 2 includes all variables used in model 1 with the addition of
the factors associated with change from our theoretical model. E-cigarette time of use (months)
was a significant predictor, with each one month increase in the time of e-cigarette use there was
a decrease in the nicotine concentration change score of 0.095 mg/ml. There was a significant
difference between individuals using e-cigarettes for a non-harm reduction reason and
individuals using e-cigarettes for a harm reduction reason. Vapers using e-cigarettes for nonharm reduction reasons had an increase of 3.087 mg/ml on the change score when compared
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vapers using e-cigarettes harm reduction reasons. Self-efficacy was a significant predictor, with
each one unit increase in the self-efficacy score, there was a decrease in the nicotine change
score of 0.340 mg/ml. Perceived severity was a significant predictor in the model with each one
unit increase in the perceived severity score, there was an increase in the nicotine change score
of 0.239 mg/ml.
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CHAPTER 5
DISCUSSION

In our sample of 356 adult vapers, about 56% were using their e-cigarettes for a harm
reduction reason of reducing cigarettes, replacing cigarettes, replacing cigarettes and reducing
nicotine concentration, or replacing another form of tobacco. The obtained sample for this study
reflects the population of e-cigarette users in the U.S. as reported by the CDC. 37 The sample had
a mean and median age of about 24 years, which matched the CDC’s report showing the
majority of users were age 18-44 years of age.37 Participants reported a decrease in selected
nicotine concentration; while this was not a statistically significant finding it does show that
vapers are decreasing their self-selected nicotine concentrations.
Total time of e-cigarette use was a significant predictor within the two linear regression
models on the self-selected nicotine concentration change score, where increases in time of use
were associated with greater decreases in their nicotine concentration change score. Vapers
utilizing the e-cigarettes for harm reductions reasons had a greater decrease in their nicotine
concentration change score than vapers using their e-cigarette for non-harm reduction reasons.
Individuals seeking harm reduction or smoking cessation may be more motivated to decrease
their nicotine concentrations and consequentially their nicotine consumption and dependence.
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Existing literature has discussed the perception of vapers that e-cigarettes can be utilized
for smoking or tobacco cessation by replacing their tobacco product with an e-cigarette and
changing their nicotine level over time to reach complete nicotine cessation. Our findings reflect
the existing literature and suggests that vapers will decrease their nicotine concentrations to a
lower level the longer they use their e-cigarette.
Self-efficacy was statistically significantly associated with decreases in the nicotine
concentration change score. within our second regression model. Individuals who believe they
can achieve smoking or nicotine cessation may be more motivated to decrease their self-selected
nicotine concentrations. Perceived severity was statistically significantly associated with increase
on the nicotine concentration change score. This does not reflect our initial hypothesis on
perceived severity as we expected individuals experiencing more side-effects associated with ecigarettes to have greater reductions in their nicotine concentrations. The remining factors
included in the theoretical framework of this study were not statistically significantly associated
with the changes in nicotine concentrations for our participants. The scores for perceived
barriers, and subjective norms were not significant predictors of the self-selected nicotine
concentration change score however, they were associated with a decrease in nicotine
concentration. While we pulled from existing surveys and literature, we did not use a validated
questionnaire, and we used more general questions around e-cigarettes instead of questions
specifically aimed at informing the nicotine change score to determine if the questions were
measuring what they intended to.
To our knowledge this study is the first to examine changes in self-selected nicotine
concentrations and factors associated with such changes, and our finding reflect current literature
on the belief of vapers that they can reduce their nicotine concentrations. 16–18,23 Our study
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highlights the importance for additional research around changes in self-selected nicotine
concentrations, and the use of e-cigarettes for harm reduction or smoking cessation purposes.
Future studies should attempt to further understand the reasons and factors associated with
change in vapers’ self-selected nicotine concentration scores to provide additional information to
the public and policy makers. These studies should attempt to use validated measures to obtain a
clearer view of each factor’s relationship with changes in vaper self-selected nicotine
concentrations, specifically focusing on harm-reduction, self-efficacy, perceived barriers, and
subjective norms.
Current literature is showing changes in the e-cigarette population towards nicotine salts
e-cigarettes, like JUULs which accounted for about 40% ($150 million) of e-cigarette sales in the
fourth quarter of 2017.39 JUULs and similar devices (like Sourin e-cigarettes) utilize a different
form of nicotine from traditional e-cigarettes, higher nicotine concentrations than traditional ecigarettes (35 mg/ml and 59 mg/ml), and have a striking appeal with a sleek, non-modifiable,
closed system device that easier to use and maintain compared to tank mod or drip mod ecigarettes.39–41 Our survey obtained information on the types of e-cigarettes used and the selfselected nicotine concentrations used by vapers. Vapers within our sample reported nicotine
levels associated with nicotine salts e-cigarettes and 26.2% of our sample reported using a vape
pen or cig-alike e-cigarette.
Scott Gottlieb, the former FDA Commissioner, made a statement in early 2018 on the
FDA’s intent to prevent the use of JUULs and other e-cigarettes by youth. 42 This statement also
provides information of the FDA’s plan considering the regulation of nicotine levels in cigarettes
to minimally or non-addictive levels and suggests that e-cigarette may offer an alternative with
potentially lower risk to adult smokers.42 In April of 2019, the FDA made a statement on a link
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between e-cigarettes and seizures in youth and young adults, potentially associated with high
levels of nicotine or the use of other substances. 43 Continued research is necessary around the
characteristics of the population using e-cigarettes, specifically around JUULs and similar
devices for their unique characteristics, high nicotine concentrations, and higher potential for
nicotine dependence in youth, young adults and, non-smokers.
This study has several limitations. First, since this is a cross-sectional observational
study, we can observe correlations, but causation cannot be drawn from the data collected. There
is also the potential for the participants to change their habits after the point of data collection.
Second, we employed a survey as the main method of our data collection, there is the chance for
socially desirable response bias as e-cigarettes and their use could be seen in a negative context
by society or portions therein. There is a potential for response bias due the recall of each
participant in addition to each participants’ honesty when responding to the surveys. Multiple
response bias was controlled for using each participants’ email address, and two responses were
excluded based on matching emails. Third, this study did not measure nicotine dependence in ecigarette users, and instead examine changes in their self-selected nicotine concentrations that
current literature supports as a method of decreasing nicotine dependence. And fourth, this study
measured the factors from our framework at the time of the survey to examine associations with
previous change and may not accurately reflect the true associations between each construct
within the framework and the self-selected nicotine change.
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CHAPTER 6
CONCLUSION

Existing literature around e-cigarettes seems to support their use for harm reduction
purposes. Smokers and other tobacco users seeking to use e-cigarettes for smoking cessation or
harm reduction may benefit from their use in decreasing their nicotine dependence or potentially
reaching cessation. However, e-cigarettes are not safe and should not be utilized by individuals
who do not already use another form of nicotine. Literature on e-cigarettes and smoking
cessation is inconclusive, necessitating continued vigilance in understanding the current
population utilizing them and any changes within the e-cigarette marketplace. The population
using e-cigarettes is constantly changing with the development of new devices like the JUUL,
and similar devices, which are appealing to the young adult and adolescent population and after
each legislative change at the federal or state level as well. Future studies should attempt to
disseminate more information on devices like the JUUL due to their higher nicotine
concentrations, appeal to young adults and adolescents, and greater potential for dependence.
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Tables
Table 1.
Descriptive Statistics of Sociodemographic Characteristics Among Survey Respondents
Sociodemographic Characteristics
n
Mean (SD)
Median
Age
356
23.747 (8.962)
23.5
Frequency
Percent
Sex
Female
152
42.7%
Male
203
57.0%
Race
Black/African American
21
5.9%
White/Caucasian
314
88.2%
Other
21
5.9%
Hispanic or Latino/a
Not Hispanic or Latino/a
349
98.3%
Hispanic or Latino/a
6
1.7%
Education
High School or Less
90
25.3%
More than High School
266
74.7%

Min
18.0

Table 2.
Descriptive Statistics of E-Cigarette (E-Cig) Characteristics of Use Among Survey Respondents
Vaper Characteristics of E-Cig Use
n
Mean (SD)
Median
Min
E-cig Use (months)
356
23.331 (20.308)
18.0
0.0
Initial Nicotine Level (mg/ml)
356
8.851 (9.515)
6.0
0.0
Current Nicotine Level (mg/ml)
356
7.767 (11.368)
5
0.0
Frequency
Percent
Plans to Change Nicotine Level
Increase
5
1.4%
Keep Same
269
75.8%
Decrease
81
22.8%
Plans to Quit E-Cig
Yes
19
5.4%
Maybe
120
33.8%
No
216
60.8%
Type of E-cig Used Most
Cig-Alike
33
9.3%
Vape Pen
60
16.9%
E-Hookah
2
0.6%
Tank Mod
225
63.2%
Drip Mod
36
10.1%
Main Reason for E-Cig Use
Reduce Cigarette Use
17
4.5%
Replace Cigarette
93
26.1%
Replace, and Reduce Nicotine Level
72
20.2%
Quit Non-Cigarette Tobacco
18
5.1%
Circumvent Smoking Ban
9
2.5%
Weight Loss/Control Appetite
12
3.4%
For Fun
61
17.1%
For a Buzz or High
52
14.6%
Other
22
6.2%
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Max
59.0

Max
126.0
59.0
60.0

Table 3.
Descriptive Statistics of Conventional Cigarette (CC) Characteristics of Use Among Survey Respondents
Vaper Characteristics of CC Use
n
Mean (SD)
Median
Min
Max
Cigarette Use (years)
316
8.005 (8.132)
5.0
0.0
40.0
Quit Attempts
309
3.201 (4.144)
2.0
0.0
25.0
Frequency
Percent
Cigarette Ever Use
Yes
316
89.5%
No
37
10.5%
At Least One Cigarette in Last Month
Yes
117
37.1%
No
198
62.9%
At Least 100 Cigarettes in Lifetime
Yes
256
81.0%
No
60
19.0%
CDC Smoker
Yes
92
29.1%
No
224
70.9%
Cessation Methods Used
Any (Yes)
205
65.3%
Nicotine Replacement Therapy (Yes)
87
27.7%
Chantix (Yes)
40
12.7%
Zyban (Yes)
5
1.6%
Behavioral Therapy/ Counseling (Yes)
7
2.2%
‘Cold Turkey’/ Willpower Alone (Yes)
185
58.9%

Table 4.
Results of Paired Samples t-Test of Current Nicotine Concentration and Initial Nicotine Concentration
Mean Nicotine Concentration
Mean Difference (SD)
95% CI of Mean Difference

p

Initial (SD)
8.851 (9.515)

0.082

Current (SD)
7.767 (11.368)

-1.084 (11.711)
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Lower
-2.305

Upper
0.136

Table 5.
Results of Linear Regression Model Examining the Associations of Respondent Sociodemographic Characteristics,
E-Cigarette (E-Cig) Use Characteristics, and Conventional Cigarette Use Characteristics on Current-Initial
Nicotine Concentration Change Score
Variable
Regression Coefficient (Unstandardized)
Regression
p value

Constant
E-Cig Use Characteristics
E-Cig Time (months)
Use Most
Harm
Reduction
Non-Harm
Reduction
Other

9.769

Coefficient
(Standardized
)
-

0.282

-0.159
-

-0.039
-

-0.170
-

0.001
-

1.488

0.347

6.200

-

0.028

2.476
1.436

-3.370
-0.910

6.371
4.739

-

0.545
0.183

1.368
1.401
0.138

-0.387
-5.148
-0.397

4.995
0.363
0.144

-0.086

0.093
0.089
0.360

-

0.117
1.228
-

-0.340
-2.241
-

0.118
2.591
-

-0.086
-

0.342
0.887
-

1.356

2.513

-3.587

6.299

-

0.590

-1.978
-

2.432
-

-6.762
-

2.805
-

-

0.416
-

5.001

4.480

-3.812

13.814

-

0.265

-

-

-

-

-

-

0.557

1.376

-2.150

3.264

-

0.686

Estimate

SE

95% CI

3.457

3.208

-2.854

-0.099
-

0.031
-

3.273
1.501

E-Cig Most

Customizable
Non1.915
Customizable
Conventional Cigarette Use Characteristics
CDC Current
No
Smoker
Yes
2.304
Cessation Any No
Yes
-2.392
Cigarette Time (years)
-0.126
Sociodemographic Characteristics
Age (years)
Sex
Race

-0.111
Female

-

Male

0.175

White/
Caucasian
Black/ African
American
Other
Hispanic/
Not Hispanic/
Latino/a
Latino/a
Hispanic/
Latino/a
Education
High School or
Less
More than High
School
R2 = 0.196 | F = 6.133 (p<0.0001)
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Table 6.
Results of Linear Regression Model Examining the Associations of Respondent Sociodemographic Characteristics,
E-Cigarette (E-Cig) Use Characteristics, Conventional Cigarette Use Characteristics,
and Factors Associated with Change from Theoretical Model on Current-Initial Nicotine Concentration Change
Score
Variable
Regression Coefficient (Unstandardized)
Regression
p value
Coefficient
Estimate
SE
95% CI
(Standardized)
Constant
6.482
10.285
-13.754
26.717
0.529
E-Cig Use Characteristics
E-Cig Time (months)
-0.095
0.031
-0.156
-0.035
-0.164
0.002
Use Most
Harm
Reduction
Non-Harm
Reduction
Other

3.087

1.501

0.134

6.040

-

0.041

2.000

2.477

-2.874

6.874

-

0.420

Customizable
Non1.236
Customizable
Conventional Cigarette Use Characteristics
CDC Current
No
Smoker
Yes
1.821
Cessation Any No
Yes
-0.098
Cigarette Time (years)
-0.092
Socio-Demographic Characteristics

1.486

-1.688

4.161

-

0.406

1.363
0.139
0.140

-0.861
-4.997
-0.372

4.503
0.553
0.177

-0.068

0.183
0.116
0.484

Age (years)

-0.108

0.119

-0.343

0.127

-0.084

0.368

Female

-

-

-

-

-

-

Male

0.148

1.238

-2.287

2.583

-

0.905

-

-

-

-

-

-

1.755

2.554

-3.269

6.780

-

0.492

-1.197
-

2.453
-

-6.023
-

3.629
-

-

0.626
-

4.571

4.473

-4.228

13.370

-

0.308

-

-

-

-

-

-

0.307

1.383

-2.414

3.027

-

0.825

0.239
0.347
0.057
-0.505
0.025
-0.340
-0.182

0.115
0.227
0.170
0.269
0.225
0.139
0.179

0.014
-0.099
-0.277
-1.034
-0.419
-0.615
-0.534

0.465
0.793
0.391
0.024
0.469
-0.066
0.170

0.125
0.103
0.021
-0.104
0.006
-0.132
-0.062

0.038
0.127
0.736
0.061
0.912
0.015
0.309

E-Cig Most

Sex
Race

White/
Caucasian
Black/ African
American
Other
Hispanic/
Non-Hispanic/
Latino/a
Latino/a
Hispanic/
Latino/a
Education
High School or
Less
More than High
School
Factors Associated with Change
Perceived Severity
Perceived Susceptibility
Perceived Benefits
Perceived Barriers
Cues to Action
Self-Efficacy
Subjective Norms
R2 = 0.232 | F = 2.176 (p=0.036)
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APPENDIX A: Statements Utilized to Measure Theoretical Model of Health-Related
Beliefs Regarding E-Cigarettes
Factor Associated

Statements Utilized to Measure Theoretical Model of Health-Related

with Change

Beliefs Regarding E-Cigarettes

Perceived Severity

I cough when using my electronic cigarette
I get headaches when using my electronic cigarette
My throat gets sore/dry when I use my electronic cigarette
I am addicted to my electronic cigarette
I can't leave my house without my electronic cigarette
I have to use my electronic cigarette at work/school

Perceived

Electronic cigarettes are addictive

Susceptibility

I feel healthy using my electronic cigarette
I crave using my electronic cigarette
Electronic cigarettes are safe

Perceived Benefit

Electronic cigarettes are safer than tobacco cigarettes around my friends and family
Electronic cigarettes are safer around my pets
Electronic cigarettes can be used to quit smoking tobacco cigarettes
Electronic cigarettes are safer than tobacco cigarettes
I cough more using tobacco cigarettes than electronic cigarettes

Perceived Barrier

I am saving money with my electronic cigarette
Electronic cigarettes can be used in more places than tobacco cigarettes

Cues to Action

My friends and family encourage me to use my electronic cigarette
My family wants me to stop using my electronic cigarette
My friends want me to stop using my electronic cigarette

Self-Efficacy

I am able to taper down my nicotine level over time
I want to stop using my electronic cigarette
I believe I can stop using my electronic cigarette
I don't want to stop using my electronic cigarette
I believe my electronic cigarette will help me quit smoking tobacco cigarettes

Subjective Norms

Electronic cigarettes are socially accepted
I think my friends approve of me using my electronic cigarette
I think my family approves of me using my electronic cigarette
My coworkers/fellow students don't mind me using my electronic cigarette
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APPENDIX B: Theoretical Framework Model 24,26,29,30

Perceived Severity
How Vapers See the
Severity of Side Effects
Perceived Susceptibility

Perceived Threat

Vapers Perceived Risk
for a Side Effect

Action or
Change in Behavior
Changes in Nicotine
Level

Perceived Benefits
Less Cigarette Use or
Less Side Effects
Compared to Tobacco
Use

(Perceived Benefits)
minus (-)
(Perceived Barriers)

Perceived Barriers
Legal Restrictions or
Financial Difficulty

Cues to Action
Outside Support to Quit
Smoking
Self-Efficacy
How Driven and SelfMotivated a Vaper is to
Perform and Action
Subjective Norms
What a Vaper’s Peers
Think About Vaping
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APPENDIX C: Research Consent Form

Consent to Participate in Research
Study Title: Two Surveys: Questions on Electronic Cigarette History of Use, Reasons for Use,
and Patterns of Use
Investigator
David D. Allen III, B.A.
Department of Pharmacy Administration
223 Faser Hall
University of Mississippi
University, MS 38677
(330) 283-6224
ddallen@go.olemiss.edu

Faculty Sponsor
Yi Yang, MD, Ph.D.
Department of Pharmacy Administration
223 Faser Hall
University of Mississippi
University, MS 38677
(662) 915-1062
yiyang@olemiss.edu

The purpose of this study
We want to know how and why you use your electronic cigarette and to see if there are any
changes in the next six (6) months.
What you will do for this study
You will be completing two surveys. One in the next few days, and one in six (6) months
1. You must be at least 18 years old to participate in this study.
2. You must currently use an electronic cigarette product to participate in this research.
3. You must have internet access, via a computer, tablet, or phone, to complete the survey.
4. Your email address will be asked for at the bottom of this consent form. Your email
address will allow us to connect your answers in the first survey to your answers in the
second survey.
a. Please provide an email you use and check on a regular basis.
5. First Survey
a. You will receive this survey within forty-eight (48) hours after completing this
consent form.
b. This survey should take you about fifteen (15) to twenty (20) minutes to
complete.
c. There are fifty-two (52) questions, and 2 information statements.
i. These questions will ask you about your current and past electronic
cigarette and conventional (tobacco) cigarette use.
ii. There are five (5) questions asking for your demographic information
(sex, race/ethnicity, age, and educational attainment).
iii. You are only required to complete nine (9) questions.
 Qualtrics will inform you if you missed a required question and
will ask you to complete it before continuing.
iv. While, you are only required to complete nine (9) of the fifty-two (52)
questions, we encourage you to answer all the questions as this will best
help out our study.
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d. The first question will contain David D. Allen III’s contact information if you
have any questions or issues with the survey.
e. At the completion of this survey, you will receive $5.00 Amazon e-gift card in
your email within ten (10) business days.
6. Second Survey (Last Survey)
a. You will receive an email reminding you that this survey is coming up within two
weeks of you receiving it.
b. You will receive this survey about six (6) months after completing the first
survey.
c. This survey should take you about ten (10) to fifteen (15) minutes to complete.
d. This survey will contain less questions than the First Survey.
e. At the completion of this survey, you will receive $5.00 Amazon e-gift card in
your email within ten (10) business days.
Time required for this study
This study will take about twenty (20) minutes for the 1st survey, and fifteen (15) minutes for the
2nd survey – for a total of thirty-five (35) minutes.
Possible risks from your participation
Answering survey questions on your electronic cigarette and convention (tobacco) cigarette use
may be stressful. Please see the Confidentiality section for information on how we minimize the
risk of a breach of confidentiality.
Benefits from your participation
You should not expect benefits from participating in this study. However, you might experience
satisfaction from contributing to the scientific knowledge on and around electronic cigarettes.
Also, answering the survey questions might make you more aware of habits you’d like to
change, sometimes this can help lead to improved habits.
Incentives
You will receive a one (1) $5.00 Amazon e-gift card via email within ten (10) business days after
completing each survey, for a total of two (2) Amazon e-gift cards worth a total of $10.00.
Confidentiality
Your email address(es), phone number (where applicable), and responses will remain in
password protected electronic files on a password protected laptop. Only research team members
will have access to your email address(es), phone number, and responses. We will protect
confidentiality by coding and then separating your email address(es), and phone number from
your responses into a separate password protected document. At the end of the study, your email
address(es), and phone number will be deleted along with the password protected file to further
protect your identity.
Members of the Institutional Review Board (IRB) – the committee responsible for reviewing the
ethics of, approving, and monitoring all research with humans – have authority to access all
records. However, the IRB will request identifiers only when necessary. We will not release
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identifiable results of the study to anyone else without your written consent unless required by
law.
Right to Withdraw
You do not have to volunteer for this study, and there is no penalty if you refuse. If you start the
study and decide that you do not want to finish, just close your web browser. Whether or not
you participate or withdraw will not affect your current or future relationship with the
Department of Pharmacy Administration, or with the University, and it will not cause you to lose
any benefits to which you are entitled.
The researchers may stop your participation in the study without your consent and for any
reason, such as protecting your safety or protecting the integrity of the research data. If the
researcher terminates your participation, any incentives will be prorated based on the amount of
time you spent in the study.
IRB Approval
This study has been reviewed and approved by The University of Mississippi’s Institutional
Review Board (IRB). The IRB has determined that this study fulfills the human research subject
protections obligations required by state and federal law and University policies. If you have any
questions or concerns regarding your rights as a research participant, please contact the IRB at
(662) 915-7482 or irb@olemiss.edu.
Please email, or call the primary researcher, David D. Allen III, if there is anything that is not
clear or if you need more information. When all your questions have been answered, you can
then decide if you want to be in the study or not.
Statement of Consent
I have read the above information. I have been given an unsigned copy of this form. I have had
an opportunity to ask questions, and I have received answers. I am at least 18 years old. I consent
to participate in the study by providing my email address to receive the surveys.
Email Address (Please print, in the field below)
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Back-up Email Address or Telephone Number (Please print, in the field below)
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APPENDIX D: Survey
Electronic Cigarette History of Use, Reasons for Use, and Patterns of Use

Start of Block: E-Cigarette Survey

Q1
Please Contact David Allen if you have any questions or issues on/with the survey.

David D. Allen III
(330) 283-6224
Ddallen@go.olemiss.edu

Q2
How old are you? (years)
________________________________________________________________
Skip To: Q55 If How old are you? (years) < 18

Q3 Do you currently use any of the following: electronic cigarette, vape pen, vape pipe, vape mod, or
other vape product?

o Yes
o No
Skip To: Q55 If Do you currently use any of the following: electronic cigarette, vape pen, vape pipe, vape mod, o...
= No

57

Q4
What is an e-mail address we can use to reach you? Your email will also be used to compare your
answers between this survey and the next survey we send you. Please remember this is also the email you
will receive your Amazon e-gift card at upon completion of this survey.
________________________________________________________________
Skip To: End of Survey If What is an e-mail address we can use to reach you? Your email will also be used to
compare your a... Is Empty

Q5 How long have you used an electronic cigarette or related product? (months)
________________________________________________________________

Q6 Are you planning to stop using your electronic cigarette in the next six (6) months?

o Yes
o Maybe
o No

Q7 What nicotine level e-liquid are you currently using in your electronic cigarette? (in milligrams per
milliliter, mg/ml | example: 6)
________________________________________________________________
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Q8 Have you changed the nicotine level in your e-liquid since you started vaping?

o Yes
o No
Skip To: Q12 If Have you changed the nicotine level in your e-liquid since you started vaping? = No

Q9 When you first started using your electronic cigarette, what nicotine level e-liquid were you using in
your electronic cigarette? (in milligrams per milliliter, mg/ml | example: 6)
________________________________________________________________

Q10 About how long has it been since you last changed your e-liquid nicotine level? (months)
________________________________________________________________

Q11 Before you changed your nicotine level, what nicotine level e-liquid were you using in your
electronic cigarette? (in milligrams per milliliter, mg/ml | example: 6)
________________________________________________________________

Q12 Are you planning to change the nicotine level of the e-liquid you use in the next six (6) months?

o Yes, increase
o No, keep the same
o Yes, decrease
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Q13
Approximately, how many milliliters (ml) of e-liquid have you used in the past month? (number of
milliliters | ex: 120)
________________________________________________________________

Q14 On average, about how much do you spend on e-liquid over a month? (dollars and cents, 00.00)
________________________________________________________________

Q15 On average, about how much do you spend on replacement coil, cotton, wire, or other electronic
cigarette parts over a month? (dollars and cents, 00.00 | please exclude the cost of e-liquid)
________________________________________________________________

Q16 How many days do you use your electronic cigarette in an average month? (0 to 30)
________________________________________________________________

Q17
How many days did you crave using your electronic cigarette in the past month? (0 to 30)
________________________________________________________________
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Q18 On average, how many times a day do you puff from your electronic cigarette? (puffs)
________________________________________________________________

Q19
What types of electronic cigarettes have you used? (please select all that apply)
Cig-alike (Blu, N-Joy, etc.)
Vape Pen
E-Pipe
E-Hookah
Vape Mod with a Tank Atomizer
Vape Mod with a Drip Atomizer
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Q20
Thinking about the list above, which type of electronic cigarette have you used the most? (please select
only one)

o Cig-alike (Blu, N-Joy, etc.)
o Vape Pen
o E-Pipe
o E-Hookah
o Vape Mod with a Tank Atomizer
o Vape Mod with a Drip Atomizer
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Q21 Which of the following reasons describe why you are using your electronic cigarette. (please select
all that apply)
To avoid tobacco withdrawal symptoms, by using my electronic cigarette in areas where I
am not allowed to smoke tobacco cigarettes
To quit smoking tobacco cigarettes, by reducing how many tobacco cigarettes I smoke
To quit smoking tobacco cigarettes, by replacing tobacco cigarettes with my electronic
cigarette
To quit smoking tobacco cigarettes, by replacing tobacco cigarettes with my electronic
cigarette and changing my nicotine level
To quit another form of tobacco
To control my appetite or for weight loss
I use my electronic cigarette for fun
I use my electronic cigarette for the buzz that nicotine gives me
Other, not listed here
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Q22 Thinking about the previous question, which reason do you feel most closely describes why you use
your electronic cigarette. (please select only one)

o
To avoid tobacco withdrawal symptoms, by using my electronic cigarette in areas where I am not
allowed to smoke tobacco cigarettes
o To quit smoking tobacco cigarettes, by reducing how many tobacco cigarettes I smoke
o To quit smoking tobacco cigarettes, by replacing tobacco cigarettes with my electronic cigarette
o
To quit smoking tobacco cigarettes, by replacing tobacco cigarettes with my electronic cigarette
and changing my nicotine level
o To quit another form of tobacco
o To control my appetite or for weight loss
o I use my electronic cigarette for fun
o I use my electronic cigarette for the buzz that nicotine gives me
o Other, not listed here
Display This Question:
If Thinking about the previous question, which reason do you feel most closely describes why you use... =
Other, not listed here
Or Which of the following reasons describe why you are using your electronic cigarette. (please sele... =
Other, not listed here

Q23 You have selected other in one of the previous questions, please explain the reason why you use
your electronic cigarette.
________________________________________________________________
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Q24 Which of the following types of flavors do you use for your e-liquid? (please select all that apply)
Tobacco
Menthol
Fruit
Dessert
Candy
Beverage
Other

Q25 Thinking about the above, which of the following types of flavors do you use most often for your eliquid?

o Tobacco
o Menthol
o Fruit
o Dessert
o Candy
o Beverage
o Other
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Display This Question:
If Which of the following types of flavors do you use for your e-liquid? (please select all that apply) = Other
Or Thinking about the above, which of the following types of flavors do you use most often for your... = Other

Q26 You have selected other in one of the previous questions, please describe the flavor.
________________________________________________________________

Q27 Have any of your friends or family members ever used an electronic cigarette? Please select one
option for each of the following.
Yes
Immediate Family

Other Family

Close Friends

Other Friends

No

o
o
o
o

o
o
o
o

Uncertain/ Don't Know

o
o
o
o

Skip To: Q30 If Have any of your friends or family members ever used an electronic cigarette? Please select one o...
= Immediate Family
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Q28 Do any of your friends or family members currently use electronic cigarettes? Please select one
option for each of the following.
Yes
Immediate Family

Other Family

Close Friends

Other Friends

No

o
o
o
o

o
o
o
o

Uncertain/ Don't Know

o
o
o
o

Q29 Have any of your friends or family members ever used their electronic cigarette to help them quit
smoking tobacco cigarettes? Please select one option for each of the following.
Yes
Immediate Family

Other Family

Close Friends

Other Friends

No

o
o
o
o

o
o
o
o
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Uncertain/ Don't Know

o
o
o
o

Q30
What is your sex.

o Female
o Male
Q31
Are you Hispanic or Latino?

o No
o Yes, I am Hispanic or Latino/Latina
Q32 What race or races do you consider yourself to be? (please select at least one, or all that apply)
American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or other Pacific Islander
White or Caucasian
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Q33
Please select the highest level of education you have completed.

o Less than high school
o High school graduate
o Some college
o 2-year degree (ex. Associate's degree)
o 4-year degree (ex: Bachelor's degree)
o Professional degree
o Master's degree
o Doctoral degree
Q34 Have any of your friends or family members ever smoked tobacco cigarettes? Please select one
option for each of the following.
Yes
Immediate Family

Other Family

Close Friends

Other Friends

No

o
o
o
o

o
o
o
o

Uncertain/ Don't Know

o
o
o
o

Skip To: Q36 If Have any of your friends or family members ever smoked tobacco cigarettes? Please select one
opt... = Immediate Family
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Q35 Do any of your friends or family members currently smoke tobacco cigarettes? Please select one
option for each of the following.
Yes
Immediate Family

Other Family

Close Friends

Other Friends

No

o
o
o
o

o
o
o
o

Q36 Have you ever smoked tobacco cigarettes?

o Yes
o No
Skip To: Q48 If Have you ever smoked tobacco cigarettes? = No

Q37 Have you smoked at least one (1) tobacco cigarette in the last month?

o Yes
o No
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Uncertain/ Don't Know

o
o
o
o

Q38 Have you smoked at least 100 tobacco cigarettes (5 packs) in your lifetime?

o Yes
o No

Q39 How many years have you smoked tobacco cigarettes over your life? (years)
________________________________________________________________

Q40 On average, how much do/did you spend on tobacco cigarettes over a month? (dollars and cents:
00.00)
________________________________________________________________

Q41 Do you now smoke tobacco cigarettes everyday, some days, or never?

o Everyday
o Some days
o Never
Skip To: Q44 If Do you now smoke tobacco cigarettes everyday, some days, or never? = Everyday

Q42 When you smoked, how many tobacco cigarettes did you smoke in a day on average? (cigarettes)
________________________________________________________________
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Q43 How many months has it been since you quit smoking tobacco cigarettes? (months)
________________________________________________________________
Skip To: Q46 If How many months has it been since you quit smoking tobacco cigarettes? (months) Is Not Empty

Q44 On average, how many tobacco cigarettes do you smoke each day? (cigarettes)
________________________________________________________________

Q45 Are you trying to reduce how often you smoke tobacco cigarettes?

o Yes
o No

Q46 In the past, about how many times have you tried to quit smoking tobacco cigarettes? (number of
attempts)
________________________________________________________________
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Q47
Have you tried using any of the following methods to quit smoking tobacco cigarettes? (please
select all that apply)
Nicotine Replacement Therapy (nicotine gum nicotine patches, or nicotine lozenges)
Chantix (varenicline tartrate)
Zyban (bupropion hydrochloride)
Cold turkey/ Willpower alone
Counseling/ Behavioral therapy
None of these
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Q48 Please identify your level of agreement for each of the following statements. (Strongly agree to
Strongly disagree)
Strongly
agree
Electronic
cigarettes can
be used to
quit smoking
tobacco
cigarettes

Agree

Neither
agree nor
disagree

Somewhat
agree

Somewhat
disagree

Disagree

Strongly
disagree

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Electronic
cigarettes are
safe

o

o

o

o

o

o

o

Electronic
cigarettes are
addictive

o

o

o

o

o

o

o

Electronic
cigarettes are
socially
accepted

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Electronic
cigarettes are
safer than
tobacco
cigarettes

Electronic
cigarettes are
safer than
tobacco
cigarettes
around my
friends and
family
Electronic
cigarettes are
safer around
my pets
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Q49 Please identify your level of agreement for each of the following statements. (Strongly agree to
Strongly disagree)
Strongly
agree
I can tell
when I need
to add more
e-liquid to
my
electronic
cigarette
I feel
healthy
using my
electronic
cigarette
I cough
when using
my
electronic
cigarette
I cough
more using
tobacco
cigarettes
than
electronic
cigarettes
I get
headaches
when using
my
electronic
cigarette
My throat
gets
sore/dry
when I use
my
electronic
cigarette
I am able to
taper down
my nicotine
level over
time

Agree

Neither
agree nor
disagree

Somewhat
agree

Somewhat
disagree

Disagree

Strongly
disagree

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q50 Please identify your level of agreement for each of the following statements. (Strongly agree to
Strongly disagree)
Strongly
agree
I am
saving
money
with my
electronic
cigarette
I want to
stop using
my
electronic
cigarette
I want to
quit
smoking
tobacco
cigarettes
I believe I
can quit
smoking
tobacco
cigarettes

I believe I
can stop
using my
electronic
cigarette
I believe
my
electronic
cigarette
will help
me quit
smoking
tobacco
cigarettes

Agree

Somewhat
agree

Neither
agree
nor
disagree

Somewhat
disagree

Disagree

Strongly
disagree

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q51 Please identify your level of agreement for each of the following statements. (Strongly agree to
Strongly disagree)
Strongly
agree

Agree

Somewhat
agree

Neither
agree
nor
disagree

Somewhat
disagree

Disagree

Strongly
disagree

I crave
using my
electronic
cigarette

o

o o

o

o

o

o

I crave
smoking
tobacco
cigarettes

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

I don't want
to stop
using my
electronic
cigarette
I don't want
to quit
smoking
tobacco
cigarettes
I am
addicted to
my
electronic
cigarette
I can't leave
my house
without my
electronic
cigarette
I have to
use my
electronic
cigarette at
work/school
Electronic
cigarettes
can be used
in more
places than
tobacco
cigarettes
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Q52 Please identify your level of agreement for each of the following statements. (Strongly agree to
Strongly disagree)
Strongly
agree
My family
wants me
to quit
smoking
tobacco
cigarettes
My family
is
supportive
of me
quitting
tobacco
cigarettes
My
friends
want me
to quit
smoking
tobacco
cigarettes
My
friends are
supportive
of me
quitting
tobacco
cigarettes
E-liquid
flavors
help me to
quit
smoking
tobacco
cigarettes
E-liquid
flavors
help me to
not crave
smoking
tobacco
cigarettes

Agree

Somewhat
agree

Neither
agree
nor
disagree

Somewhat
disagree

Disagree

Strongly
disagree

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o
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Q53 Please identify your level of agreement for each of the following statements. (Strongly agree to
Strongly disagree)
Strongly
agree
My friends and
family encourage
me to use my
electronic
cigarette

Agree

Somewhat
agree

Neither
agree
nor
disagree

Somewhat
disagree

Disagree

Strongly
disagree

o

o o

o

o

o

o

My family wants
me to stop using
my electronic
cigarette

o

o o

o

o

o

o

My friends want
me to stop using
my electronic
cigarette

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

o

o o

o

o

o

o

My
coworkers/fellow
students don't
mind me using
my electronic
cigarette
I think my
friends approve
of me using my
electronic
cigarette
I think my
family approves
of me using my
electronic
cigarette
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Q54
Thank you for completing this survey. Your participation is greatly appreciated.
Your Amazon e-gift card will be emailed to you within the next 10 business days.
Please note that you will receive the next survey via email in 6 months.

Display This Question:
If Thank you for completing this survey. Your participation is greatly appreciated. Your Amazon e-gi... Is Not
Displayed

Q55 Thank you for your time but you have not qualified to complete this survey.
End of Block: E-Cigarette Survey
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VITA
Born in 1992, David D. Allen III has had a wide variety of experiences during his
upbringing. While born in Kentucky, he was raised primarily in the Panhandle of Texas and
northeast Ohio. David has been exposed to a plethora of lifestyles in different settings throughout
his lifetime, seeing the ups and downs of individual and societal issues. This Thesis focused on
something close to his passion, to enable individuals to reach nicotine cessation through their
own means and hopefully prevent the known adverse events associated with tobacco use.
David completed his Bachelor’s in Political Science at the University of North Texas in
Denton, Texas. After a break year, he began the pursuit of his Master’s and PhD in
Pharmaceutical Sciences with an emphasis in Pharmacy Administration. His experiences in
healthcare policy, public health, and pharmacoeconomics enabled him to bring this Master’s
Thesis to light under the guidance of a body of supportive faculty members and fellow student
colleagues.
David has been associated with a small amount of publications at this time but aims to
grow his peer-reviewed repertoire after the dissemination of this Thesis publication. His
maintains his interest in research looking at potentially harm reducing strategies to aid in the
cessation of various substances, including nicotine. In doing so, he hopes to further this research
moving forward into the development, enactment, and future dissemination of his Doctoral
Dissertation.
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